Rhythm Pharmaceuticals Inc. (RYTM)
NASDAQ: RYTM · Pharmaceutical Preparations · Boston, MA
Our rating: Positive
Call changed from Cautious to Positive at $110.68, moderate conviction, November 4, 2026.
Breaks if: The Positive call breaks if reported revenue growth decelerates below 20% year-over-year in either of the next two quarterly filings — that pace would signal the commercial ramp is plateauing well short of what the 40x revenue multiple requires. It also breaks if annual free cash flow deteriorates to worse than -$175M in the next reported period, meaning the gap between accounting losses and actual cash outflows is narrowing in the wrong direction rather than compressing toward breakeven.
Key figures
| Market value | $7.8B |
|---|---|
| Revenue, last 12 months | $281M |
| Net income, last 12 months | −$194M |
| Free cash flow, last 12 months | n/a |
| Price to earnings | n/a |
| Free cash flow yield | n/a |
| Dividend yield | 0.0% |
| Operating margin | −66.7% |
| Return on equity | −163.7% |
| Beta to the S&P 500 | 0.95 |
| Volatility, annualized | 55.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $92M | 79.6% | $-0.61 | n/a |
| June 30, 2026 | $71M | 46.9% | $-0.73 | n/a |
| March 31, 2026 | $60M | 83.8% | $-0.83 | n/a |
| December 31, 2025 | $57M | 36.9% | $-0.73 | −$26M |
| September 30, 2025 | $51M | 54.3% | $-0.82 | n/a |
| June 30, 2025 | $49M | 66.8% | $-0.75 | n/a |
| March 31, 2025 | $33M | 25.9% | $-0.81 | n/a |
| December 31, 2024 | $42M | 72.6% | $-0.72 | n/a |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.09B: Claude 72%, Gemini 92%, Mistral 80%
- Diluted earnings per share are above zero: Claude 4%, Gemini 5%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 8%, Gemini 7%, Mistral 10%
20 ledger entries and 27 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.